Boston Scientific (NYSE:BSX) said today that it closed its $210 million buyout of EndoChoice (NYSE:GI) and its line of devices for treating gastrointestinal disease. The $8-per-share tender offer was originally slated to expire at midnight Nov. 4. Marlborough, Mass.-based Boston Scientific later moved the deadline out to Nov. 21. they September. Alpharetta, Ga.-based EndoChoice took itself public in June 2015 […]
Boston Scientific extends $210 million tender offer for EndoChoice
Boston Scientific (NYSE:BSX) said today that it’s extending its $210 million tender offer for EndoChoice (NYSE:GI) and its line of devices for treating gastrointestinal disease. The $8-per-share tender offer was slated to expire at midnight Nov. 4. Marlborough, Mass.-based Boston Scientific said it’s moving the deadline out to Nov. 21 “to allow additional time for the satisfaction of […]
Boston Scientific launches tender offer for EndoChoice
Boston Scientific (NYSE:BSX) said today that it launched the tender offer for its pending, $210 million acquisition of EndoChoice (NYSE:GI) and its line of devices for treating gastrointestinal disease. The $8-per-share tender offer is slated to expire at midnight Nov. 4, Marlborough, Mass.-based Boston Scientific said. EndoChoice directors, affiliated funds and other stockholders have already agreed […]
Boston Scientific to pay $210m for EndoChoice
Boston Scientific (NYSE:BSX) said today that it agreed to pay $210 million for EndoChoice (NYSE:GI) and its line of devices for treating gastrointestinal disease. The $8-per-share offer is slated to close by the end of the year, the companies said. EndoChoice took itself public in June 2015 with an IPO that brought in some $96 million. “The addition […]
EndoChoice wins FDA 510(k) for Lumos imaging software
EndoChoice said today it won FDA 510(k) clearance for its Lumos imaging software system, part of the company’s 3 Fuse Full Spectrum Endoscopy system, and launched the system in the U.S. The Lumos system is designed with adaptive matrix imaging to analyze and selectively enhance vascularity, surface texture and color of abnormal tissue to return more […]
EndoChoice wins FDA 510(k) for Orca endoscope valves, announces multi-product launches
EndoChoice said it won FDA 510(k) clearance for its Orca sterile, single-use air, water and suction valves designed for Olympus 160, 180 and 190 flexible endoscopes, and announced the launch of its 3rd-gen Fuse endoscopy system and RescueNet retrieval device. With the clearance for the Orca valves, as well as previous regulatory wins, EndoChoice will begin sales […]
Medtech trio sets $297m offering terms
A trio of medtech companies set terms for their upcoming public offerings today, announcing plans to raise a collective $297 million.
EndoChoice files for $115m IPO
EndoChoice said today that it filed for an initial public offering that could fetch as much as $115 million, scarcely 2 months after pulling down a $57 million funding round for its Fuse full-spectrum endoscope.
HART CEO Green bows out | Personnel Moves
Tandem Diabetes plans $60m offering | Medtech funding for the week of March 2, 2015
EndoChoice raises $57m for Fuse endoscope
EndoChoice today said it raised $57 million for its Fuse full-spectrum endoscope from a group that included prior backers and new investors.
